KalVista Pharmaceuticals, Inc.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $50.0M
- Net income
- -$183.4M
- Total assets
- $250.8M
- Market cap
- $1.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $188.0M
- Operating income
- -$188.0M
- Income tax
- $3.4M
- Net income
- -$183.4M
- EPS (basic)
- $-3.69
- EPS (diluted)
- $-3.69
Balance sheet
- Total assets
- $250.8M
- Current assets
- $241.7M
- Total liabilities
- $155.4M
- Current liabilities
- $45.2M
- Shareholders’ equity
- $95.4M
Cash flow
- Operating cash flow
- -$152.9M
- Investing cash flow
- $91.0M
- Financing cash flow
- $159.7M
- Net cash flow
- $97.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-3.69
- Shares outstanding
- 53.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 9, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $183.4M in FY2024.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KalVista Pharmaceuticals, Inc..
Write a review
News about KalVista Pharmaceuticals, Inc.
News & sentiment via Polygon.io
